Physician profile
Sumathy T Pathy
NPI 1346273158
$669.90
in general payments reported to CMS, 2019-2025
11 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.32 · 2022: $37.10 · 2023: $211 · 2024: $170 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $141.89 | 2019-2023 | Krystexxa |
| Novo Nordisk INC | $132.65 | 2024 | Rybelsus, Ozempic |
| Dexcom, INC. | $130.73 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $72.02 | 2023-2024 | Accrufer |
| Abbott Laboratories | $53.36 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Phadia US INC. | $37.10 | 2022 | |
| Sanofi Pasteur INC. | $25.33 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $23.13 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $21.09 | 2025 | Spravato |
| Xeris Pharmaceuticals, INC. | $17.88 | 2024 | Gvoke Hypopen |
| Genentech USA, INC. | $14.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumathy Pathy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.